Xenon's Phase 3 Supports A 'Buy' Despite Its Premium

Xenon Pharmaceuticals’ bull case improved after X-TOLE2 showed robust focal seizure reduction in a highly refractory patient ...

NYU Langone Health Neurologists Present Latest Clinical Findings and Research at AAN 2026

CHICAGO, April 20, 2026 /PRNewswire/ -- Experts from NYU Langone Health's Department of Neurology present their latest clinical findings and research discoveries at the American Academy of Neurology ...
The Manila Times

SnoreRX Anti-Snoring Mouthpiece Claims Evaluated: Doctor-Recommended Adjustable Mouthguard for Safer Airway Breathing Overnight

SnoreRX examines its FDA-cleared mandibular advancement mouthpiece design, 1-millimeter adjustable calibration, boil-and-bite ...
The American Journal of Managed Care

Early ALPHA3 Data Could Signal Shift to Frontline Use of CAR T in LBCL

Off-the-shelf cema-cel clears MRD at more than triple the rate of observation alone—and may propel a shift to frontline use ...
Le Lézard

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with ...

Neurocrine Biosciences, Inc. today announced the first presentation of new two-year data from the Phase 3 CAHtalyst® Adult study demonstrating sustained, substantial reductions in glucocorticoid (GC) ...